张三印, 张婷, 陈伟, 李欢, 何太平, 杨含婷, 毕增昊, 丛朝彤, 陈士林. 基于全基因组泛受体的药靶同筛中药开发与评价新策略J. 药学学报, 2025, 60(8): 2375-2388. DOI: 10.16438/j.0513-4870.2025-0377
引用本文: 张三印, 张婷, 陈伟, 李欢, 何太平, 杨含婷, 毕增昊, 丛朝彤, 陈士林. 基于全基因组泛受体的药靶同筛中药开发与评价新策略J. 药学学报, 2025, 60(8): 2375-2388. DOI: 10.16438/j.0513-4870.2025-0377
ZHANG San-yin, ZHANG Ting, CHEN Wei, LI Huan, HE Tai-ping, YANG Han-ting, BI Zeng-hao, CONG Zhao-tong, CHEN Shi-lin. A novel strategy for development and evaluation of traditional Chinese medicine based on genome-wide pan-receptor drug-target co-screeningJ. Acta Pharmaceutica Sinica, 2025, 60(8): 2375-2388. DOI: 10.16438/j.0513-4870.2025-0377
Citation: ZHANG San-yin, ZHANG Ting, CHEN Wei, LI Huan, HE Tai-ping, YANG Han-ting, BI Zeng-hao, CONG Zhao-tong, CHEN Shi-lin. A novel strategy for development and evaluation of traditional Chinese medicine based on genome-wide pan-receptor drug-target co-screeningJ. Acta Pharmaceutica Sinica, 2025, 60(8): 2375-2388. DOI: 10.16438/j.0513-4870.2025-0377

基于全基因组泛受体的药靶同筛中药开发与评价新策略

A novel strategy for development and evaluation of traditional Chinese medicine based on genome-wide pan-receptor drug-target co-screening

  • 摘要: 药靶同筛是本草基因组研究团队基于全基因组泛受体和药用动植物基因编码天然多样性成分库提出的中药开发与评价新策略。本文从基于中医临床疗效的病症新靶标发现和中药多组分靶标筛选技术、人工智能赋能药靶同筛的中药活性成分发现及机制解析等方面阐述药靶同筛策略的主要内容, 并阐明其在病(证) 靶标发现、中药新药开发、中药多靶标与途径作用机制解析、中药性味研究等方面的应用。以人类全基因组泛受体为核心的药靶同筛策略, 为中药药效物质基础及作用机制研究提供了有力支持, 有助于解决中药靶标不清、机制不明等关键核心问题, 为中药新药开发和现代化研究提供新的思路与范式。

     

    Abstract: In the present work, we propose drug-target co-screening strategy, a novel technique for Chinese medicine development and evaluation, which leverages whole-genome pan-receptors and genetically encoded natural compound libraries from medicinal plants and animals. This paper outlines the core components of the strategy, focusing on the identification of novel disease and syndrome-related targets based on clinical efficacy of Chinese medicine, multi-component target screening technologies for herbal medicine, technologies for multi-component identification and target screening and artificial intelligence-powered approaches for discovering active ingredients and elucidating their mechanisms. The strategy demonstrates broad applicability in areas such as the discovery of disease (syndrome) targets, the development of new Chinese medicine drugs, the analysis of multi-target, multi-pathway mechanism of action of Chinese medicine, and the study of drug properties including the five flavors. Centered on whole-genome pan-receptors, drug-target co-screening strategy provides a powerful framework to address key challenges in Chinese medicine research—namely, the ambiguity of therapeutic targets and unclear mechanisms of action. This approach offers strong support for mechanistic studies and paves the way for a new paradigm in modernizing and innovating Chinese medicine drug development.

     

/

返回文章
返回